Antimicrobial Therapeutics Companies

Entasis Therapeutics Announced positive Phase 3 trial results for ecneplanin, a broad-spectrum antibiotic targeting Gram-negative bacteria, showcasing potential for treating multidrug-resistant infections.

Spero Therapeutics Received FDA Fast Track designation for teixobactin, a first-in-class antibiotic with a unique mechanism of action, aiming to address life-threatening infections caused by highly resistant bacteria.

Microbiotica Ltd Launched their Live Biotherapeutic Product (LBP) platform, utilizing naturally occurring gut bacteria to restore microbial balance and combat antimicrobial resistance.

Cellectis S.A Developed phage-based therapies targeting specific bacterial strains, offering a promising alternative approach to traditional antibiotics.

Cidara Therapeutics Received FDA Breakthrough Therapy designation for CIDARA677e, a next-generation antibiotic effective against multidrug-resistant Gram-negative pathogens.

• AbbVie Inc.


• Astellas Pharma Inc.


• Bavarian Nordic AS


• Biocidium Biopharmaceuticals Inc.


• Bristol Myers Squibb Co.


• Cadila Pharmaceuticals Ltd.


• CSL Ltd.


• Emergent BioSolutions Inc.


• Hoffmann La Roche Ltd.


• Gilead Sciences Inc.


• GlaxoSmithKline Plc


• Inovio Pharmaceuticals Inc.


• Johnson and Johnson Services Inc.


• Merck and Co. Inc.


• Mitsubishi Tanabe Pharma Corp.


• Novartis AG


• Novavax Inc.


• Pfizer Inc.


• Sanofi SA


• Wockhardt Ltd.